Last reviewed · How we verify
NCT04297670
HPV Prevalence in 16-20 Year Old Males
trial testing Measurement of HPV types prevalence in HPV Infection in 681 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Laval University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 681 |
| Start date | 20 February 2020 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Measurement of HPV types prevalence
Conditions studied
- HPV Infection — all drugs for HPV Infection →
Sponsor
Laval University
Who can join
Adults 16 to 20, male only, with HPV Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In Quebec, 18 birth cohorts of girls were vaccinated against HPV (aged 9 to 29 years in 2020). With an observed vaccination coverage of \>80% an important herd effect might be expected. This study aim is to measure the HPV types prevalence in unvaccinated sexually active boys aged 16 to 20 years.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prevalence of Human Papillomavirus Genotypes in Unvaccinated 16- to 20-Year-Old Men in Quebec, Canada.
Wolfe C, Ionescu IG, Mayrand MH, Coutlée F, et al · · 2025 · cited 1× · PMID 39982898 · DOI 10.1093/infdis/jiaf094
Verify or expand the search:
- PubMed search for NCT04297670
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HPV Infection
Currently open trials in the same condition.
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07281677 — Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years · Phase 4 · recruiting
- NCT06507917 — Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for · NA · recruiting
- NCT07336134 — PopSci CHW4CervixHealth · NA · recruiting
- NCT06959563 — Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV · EARLY_PHASE1 · active not recruiting
Other Laval University trials
Trials by the same sponsor.
- NCT07491887 — Identification of Objective Metabolomics-based Biomarkers of Yogurt Consumption · NA · not yet recruiting
- NCT07366827 — Effectiveness of Motorised Lumbar Support for Non-specific Low Back Pain · NA · not yet recruiting
- NCT07317973 — A Study About Patient Decision Aids Designed to Help Parents and Guardians in Canada Make Evidence-informed, Values-cong · NA · not yet recruiting
- NCT07293312 — Optimizing the Use of Virtual Reality in Rehabilitation for Individuals With Persistent Shoulder Pain · NA · not yet recruiting
- NCT07201870 — Digital Preparation for Bariatric Surgery: Feasability Pilot Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04297670 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Laval University
- Last refreshed: 5 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04297670.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing